Citius Pharmaceuticals Inc vs T-Rex 2X Long MSTR Daily Target ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while T-Rex 2X Long MSTR Daily Target ETF trades at $2.03. Which is the better fit depends on your goals.
| CTXR | MSTU | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.82 | $106.80 |
52-Week Low | $0.53 | $1.46 |
Enterprise Value | $10.86M | — |
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
MSTU (T-REX 2X Long MSTR Daily Target ETF) trades at $1.78, down 5.07% today amid significant bearish technical signals. The leveraged ETF tracking MicroStrategy has experienced extreme volatility, with news reports indicating a 95% decline over the past year. Technical indicators show overwhelming bearish momentum with moving averages unanimously negative, while fundamental data remains unavailable for this specialized leveraged product.
The outlook remains highly speculative given the ETF's leveraged structure and dependence on MicroStrategy's Bitcoin-heavy strategy. Investment opportunity exists only for sophisticated traders comfortable with extreme volatility, while risks include daily rebalancing decay, concentration in a single stock, and amplified losses during market downturns.
Trailing returns across standard periods
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →